Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.
As of today (2026-06-25), Pulmonx's Volatility is 76.84%.
Pulmonx (NAS:LUNG) Volatility Explanation
Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.
Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.
Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Pulmonx Volatility Related Terms
LUNG vs LNSR, QTI, MDAI: Volatility Comparison
For the Medical Devices subindustry, Pulmonx's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulmonx Volatility vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's Volatility distribution charts can be found below:
* The bar in red indicates where Pulmonx's Volatility falls into.
The annualized volatility is calculated as following:
σA
=
σM
*
√12
=
√ 1/(n-1) ∑(Ri - R')^2
*
√12
Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmonx (LUNG) has a Volatility of 76.84% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Pulmonx and its competitors.
Is Pulmonx's Volatility too high?
Pulmonx's current Volatility is 76.84%. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Volatility compare to LNSR and QTI?
Pulmonx's Volatility of 76.84% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Medical Devices & Instruments company?
A good Volatility depends on the Medical Devices & Instruments industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Pulmonx and its competitors. Pulmonx's current Volatility is 76.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $7.13, compared to a current price of $1.39 — trading 80.5% below its estimated fair value. The current Volatility is 76.84%. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Pulmonx (LUNG), the current Volatility is 76.84% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulmonx (LUNG) Overvalued in 2026?
Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued.
The current stock price of $1.39 is trading 80.5% below its estimated GF Value™ of $7.13.
GuruFocus considers Pulmonx to be Possible Value Trap.
Key valuation signals for LUNG:
Volatility: 76.84%
GF Value™: $7.13 vs. price of $1.39 (80.5% below fair value)
No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score
Get the complete analysis for LUNG
Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUNG has been successfully added to your 